Hinge Health, Inc. HNGE R3KPHARMA
Company Overview
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, California.
Why Investors Should Care
Generates a return on equity of 30.4%, reflecting efficient use of shareholder capital.
Revenue has grown at a 41.7% CAGR over the past five years.
Trades at a P/E of 11.3, below the sector median of 24.8.
Maintains a net profit margin of 15.1%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $587.86M (+50.6% YoY); net profit $-528.26M.
- Trailing 12 Months Year-on-year growth — revenue +53.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 41.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 41.71% |
| 1 Year: | 53.00% |
Stock Price Performance
| 1 Year: | +59.67% |
| 6 Months: | +101.54% |
| 3 Months: | +47.45% |
| 1 Month: | +3.76% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.43 · Neutral
P/E of 11.28 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.4%.
- Compounding revenue at 41.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE Hinge Health, Inc. R3KPHARMA | 92.69 | 11.28 | $5.79B | 0.00% | -142.90% | 30.38% | 41.71% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 89.83M | 100.61M | 123.83M | 139.10M | 154.21M | 182.31M | 212.82M |
| Gross Profit | - | 66.62M | 79.26M | 100.23M | 97.76M | 126.20M | 154.23M | 183.95M |
| Operating Income | - | -17.55M | -3.85M | 13.14M | -580.67M | -6.09M | 32.07M | 40.44M |
| Net Income | -26.46M | -12.93M | 341.00K | 17.14M | -575.65M | -1.84M | 35.13M | 43.69M |
| Diluted EPS | - | -0.96 | 0.01 | 1.31 | -13.10 | -0.02 | 0.41 | 0.52 |
| R&D Expense | - | 24.92M | 23.79M | 23.50M | 279.96M | 31.92M | 30.34M | 34.06M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.40M | 587.86M |
| Gross Profit | 194.18M | 299.90M | 468.22M |
| Operating Income | -130.51M | -31.91M | -546.37M |
| Net Income | -108.14M | -11.93M | -528.26M |
| Diluted EPS | -8.31 | -0.88 | -7.77 |
| R&D Expense | 110.06M | 100.84M | 368.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 673.26M | 744.76M |
| Total Equity | -318.12M | -423.99M | -434.57M | 178.66M |
| Cash & Equivalents | - | 234.95M | 300.79M | 208.00M |
| Total Liabilities | - | - | 256.56M | 366.23M |
| Current Liabilities | - | - | 249.30M | 362.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -63.91M | 49.00M | 171.44M |
| Investing Cash Flow | 1.50M | 18.31M | -113.76M |
| Financing Cash Flow | -3.00M | -2.20M | -150.47M |
| Capital Expenditure | -4.62M | -3.77M | -6.06M |
| Free Cash Flow | -68.52M | 45.23M | 165.38M |
| Net Change in Cash | -65.41M | 65.11M | -92.79M |
| Share Buybacks | 0 | 0 | 65.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 66.3% | 76.8% | 79.6% |
| Operating Margin % | -44.6% | -8.2% | -92.9% |
| Net Margin % | -36.9% | -3.1% | -89.9% |
| ROE % | 25.5% | 2.7% | -295.7% |
| ROCE % | - | -7.5% | -142.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.72% | 3.57M | $338.81M |
| 2 | 11.2 Capital Management, LLC | 3.95% | 2.46M | $233.90M |
| 3 | Vanguard Portfolio Management LLC | 3.44% | 2.15M | $203.66M |
| 4 | Deer Management Co. LLC | 3.06% | 1.91M | $181.14M |
| 5 | Vanguard Capital Management LLC | 3.03% | 1.89M | $179.63M |
| 6 | Two Sigma Investments, LP | 2.89% | 1.81M | $171.57M |
| 7 | Fuller & Thaler Asset Management Inc. | 2.74% | 1.71M | $162.52M |
| 8 | Morgan Stanley | 2.58% | 1.61M | $153.16M |
| 9 | Franklin Resources, Inc. | 2.53% | 1.58M | $149.85M |
| 10 | Jane Street Group, LLC | 2.27% | 1.42M | $134.60M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HNGE
Stifel raises Hinge Health stock price target on strong growth outlook - Investing.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPNjF0U1UzRlRqQUwzMS1aenpwTTFtNVc4bllPY3ZwUDlQT1hmdjFMU0ZTRlNYR05aYktTTU9uMTlZVG1sYWVyTGo4WDdZTjg2dGg3OVNNQ0Fnam9KQUNUcXNHYzBYaUYzVWVYZEVpUFp3dG1oVFMyd3E1VnJOeDl6X3JjcE5fTnBGN1RQZ2…
Hinge Health (HNGE) Stock Price, News & Analysis - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFBlZlNUcHhxZDlaTW1Lb2ZjMXNxNHdxeW9JWnFKYXZxNkR6UXJ1VkFzajRFejJuTXRUUnppRUw0Vk1NTmJtaldfRG0xN1Q5SUdJSHNUVFJYNA?oc=5" target="_blank">Hinge Health (HNGE) Stock Price, News & Analysis<…
Hinge Health Inc. (HNGE) Up 13.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNNnQ5c2xrMFNJSkttTVBydXBJbWpsYzFEZlpVLXY4UFJJeURKcFZHUWlkcldaR1ZjSnYtN0RUNzI2eS02T1ZpQ0JGNGhGSGtQU3RIQmRTRC1TVGM4SXBzZUZoT2p2SUFhWmFtU09lY3AzTFc0eGRDQVAwQ1RQNVU1VVZjMnJLZmx6Mms3dW…
Venture backer sells Hinge Health (HNGE) shares around $93 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQZVpTMzNOUXk4LVE1azBYSnlvWlp1YjdYdTVlbW5YQkJuWHlOT3ctbXJxenRXbzQtRE1HZFRWVWRqY0ZBVW5PWV96dk5xZGZyY081OFRSWkZGalBGZm9wdHFKRnJHUWdwTWwyamd4UDQzaUozWG5CVTFERlYwb1o4VjBBRmo5VGo1d1paT3…
IBD Stock Of The Day, Hinge, Eyes A Fresh Entry On Earnings-Tied Rally - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNY3dhWUd3U0FleklCS1Q0MTBSSzFRX0lmYTJfYWlKZmk0bUg1dUFyYzJJNDVOeXNEUXg2dmNlVlUySVlBdlNrV2xvTEU5NjBETk1iNmJfaGI2bTI4YUZtc05VYUFpNDdzbWxfeHJHekp3dXJDRjYzdWxMWWdTeGRYX0QxWGN2VXdQXzVIX0…
Hinge Health (HNGE) Stock May Trade At A Premium As Growth Expectations Rise - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQYWVhOWp0RnNYR2diNGQ1UzNkcjF5UVJfemtGaTA0YUlKTnhQSGdDUm8zWFRyOVQ0SmFmT1RrYUFMblJUdG12NUxRc0hjcEdNanBROXYzRjVpWWt0elpnVGEweUh5blhlQndPVkVoZGVybDcxMDZLUEZsa3J0VVFsQnRpRkZ4eXo4UVhyNk…
HNGE — Frequently Asked Questions
What is the current share price of Hinge Health, Inc. (HNGE)?
As of 2026-09-19 21:16 PDT, Hinge Health, Inc. (HNGE) trades at $92.69 on NYSE. Its 52-week range is $31.17 to $92.85.
What is the market capitalisation of HNGE?
Hinge Health, Inc. (HNGE) has a market capitalisation of $5.79B on NYSE.
What is the P/E ratio of HNGE?
HNGE trades at a trailing price-to-earnings (P/E) ratio of 11.28. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 22.11.
What is the return on equity (ROE) of HNGE?
HNGE has a return on equity (ROE) of 30.38%. Its return on capital employed (ROCE) is -142.90%.
Is HNGE a good stock to buy?
This page provides a data-driven analysis of Hinge Health, Inc. (HNGE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.